Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Formycon AG's Debt-to-EBITDA or its related term are showing as below:
CHIX:FYBd'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -10.77 Med: -0.21 Max: 0.76
Current: 0.47
During the past 13 years, the highest Debt-to-EBITDA Ratio of Formycon AG was 0.76. The lowest was -10.77. And the median was -0.21.
CHIX:FYBd's Debt-to-EBITDA is ranked better than 67.85% of 311
companies
in the Biotechnology industry
Industry Median: 1.39
vs CHIX:FYBd: 0.47
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Formycon AG Debt-to-EBITDA Related Terms
Formycon AG Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Formycon AG's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:FYBD vs VRTX, REGN, RVMD: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Formycon AG's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Formycon AG Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Formycon AG's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Formycon AG's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Jun. 2026) EBITDA data.
Formycon AG (CHIX:FYBD) has a Debt-to-EBITDA of 22.77 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Formycon AG. According to the industry distribution chart, Formycon AG ranks #100 out of 311 companies in the Biotechnology industry, placing it in the top 32.2%.
Is Formycon AG's Debt-to-EBITDA too high?
Formycon AG's current Debt-to-EBITDA is 22.77. The Biotechnology industry median Debt-to-EBITDA is 1.39. Formycon AG's value of 22.77 is 1538.1% above this industry median. Based on the distribution chart, Formycon AG ranks #100 out of 311 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Formycon AG has a GF Score™ of 68/100, reflecting its overall financial health beyond just this single metric.
How does Formycon AG's Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Formycon AG ranks #100 out of 311 companies for Debt-to-EBITDA. This puts Formycon AG in the upper half of its industry. The industry median Debt-to-EBITDA is 1.39. Formycon AG's value of 22.77 is 1538.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.39, based on 311 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Formycon AG's current Debt-to-EBITDA of 22.77 is 1538.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Formycon AG. For the Biotechnology industry, the median Debt-to-EBITDA is 1.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Formycon AG's current Debt-to-EBITDA is 22.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Formycon AG stock overvalued right now?
Formycon AG (CHIX:FYBD) has a current Debt-to-EBITDA of 22.77. The stock's GF Value™ is €106.36, compared to a current price of €63.30 — trading 40.5% below its estimated fair value. The current Debt-to-EBITDA is 22.77 and 1538.1% above the Biotechnology industry median of 1.39. Formycon AG's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Formycon AG (CHIX:FYBD), the current Debt-to-EBITDA is 22.77 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Formycon AG (CHIX:FYBD) Overvalued in 2026?
Based on GuruFocus' analysis, Formycon AG stock appears to be undervalued.
The current stock price of €63.30 is trading 40.5% below its estimated GF Value™ of €106.36.
Key valuation signals for CHIX:FYBD:
Debt-to-EBITDA: 22.77
GF Value™: €106.36 vs. price of €63.30 (40.5% below fair value)
Industry Position: 1538.1% above the Biotechnology median (#100 of 311)
No single metric tells the full story. See the CHIX:FYBD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Formycon AG is an independent developer of high-quality biosimilars, which are follow-on products to biopharmaceutical drugs. The Company focuses on expanding and further developing its scalable biosimilar platform, which includes approved and pipeline products across ophthalmology, immunology, and immuno-oncology. Its key products include FYB201 (ranibizumab), FYB202 (ustekinumab), FYB203 (aflibercept), FYB206 (pembrolizumab), and FYB208 (dupilumab), along with additional biosimilar candidates in various stages of development. The Company generates maximum revenue from Switzerland.
68GF Score
Get the complete analysis for CHIX:FYBD
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:FYBD has been successfully added to your 
